Relationship of Leptin with adiposity and inflammation and Resistin with disease severity in Psoriatic patients undergoing anti‐TNF‐alpha therapy

Pina, Trinitario; Genre, Fernanda; López‐Mejías, Raquel; Armesto, Susana; Ubilla, Begoña; Mijares, Verónica; Dierssen-Sotos, Trinidad; González‐López, Marcos A.; González‐Vela, M. Carmen; Blanco, Ricardo; Hernández, José L.; Llorca, Javier

doi:10.1111/jdv.13131

Cited by 31 publications

(44 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The changes of adipokines levels during treatment with TNFi in chronic inflammatory conditions has already been studied. When the changes in proinflammatory adipokines (such as resistin and chemerin) were considered, the results were not univocal (20)(21)(22). Also for adiponectin (a cytokine with antinflammatory action), the effects of TNFi treatment was not consistent (23)(24)(25).…”

Section: N Resultsmentioning

confidence: 97%

Effects of secukinumab on serum adipocytokines: preliminary data

et al. 2017

View full text Add to dashboard Cite

SUMMARYPsoriatic arthritis (PsA) is a chronic inflammatory disease that affects joints, connective tissues and the axial skeleton. Metabolic syndrome is an independent risk factor for psoriasis (Pso) development and is associated with more severe forms of Pso. Adipocytokines are secreted by white adipose tissue and are thought to link obesity with the development of metabolic and cardiovascular diseases. Secukinumab is a new monoclonal antibody with a different mechanism of action. This antibody selectively binds to and neutralizes interleukin-17 (IL-17) and it has shown efficacy in the treatment of PsA. The aim of this study was to evaluate the possible interferences of secukinumab on different adipocytokines. We enrolled 28 patients with PsA, classified with the CASPAR criteria. Serum samples were stored at baseline and then at the first, the third and the sixth month of therapy. Resistin, chemerin, adiponectin and C-reactive protein (CRP) were dosed. When tested globally, none of the adipokine tested showed any statistically significant variation. However, when the male group was tested, both resistin and chemerin at M6 showed a significant decrease from baseline. CRP did not show any variation at any time point. Our study demonstrated that treatment with secukinumab has little influence on the levels of adipokines tested within the first six months of treatment even though it might exert different influence between males and females from a metabolic perspective. Further studies with greater numbers of patients are needed to determine whether these preliminary results have clinical relevance.Key words: Psoriasis; psoriatic arthritis; secukinumab; adipokines; resistin; adiponectin; chemerin. Reumatismo, 2017; 69 (3): 105-110 n INTRODUCTION P soriasis (Pso) is a common chronic inflammatory disease involving the skin that can be associated with several comorbidities, one of which is psoriatic arthritis (PsA) (1). Psoriatic arthritis is a chronic, systemic inflammatory disease affecting peripheral joints, connective tissues, and the axial skeleton and is associated with psoriasis of the skin and nails (1). Patients with Pso and PsA share obesity (and related complications) and cardiovascular (CV) diseases. Chronic inflammation in Pso and PsA can partially explain the development of atherosclerosis and CV diseases, but also the concomitant alterations in the glucose metabolism (diabetes and insulin resistance) and lipids (dyslipidaemia) enhance this risk (2). Systemic inflammation induced by obesity and metabolic syndrome could exacerbate local inflammation, worsening both Pso and PsA (3). Indeed, increasing evidence is suggesting that metabolic syndrome is an independent risk factor for Pso development and is associated with more severe forms of Pso (3). Nowadays, adipose tissue is considered as an active endocrine and immune organ, producing various cytokines, named adipocytokines, and they link together inflammation and metabolic disorders (4). Adipocytokines, in cooperation with macrophages and T cells, ind...

show abstract

Section: N Resultsmentioning

confidence: 97%

Effects of secukinumab on serum adipocytokines: preliminary data

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Notwithstanding mounting evidence suggesting the TNF-α contribution to insulin resistance, anti-TNF-α-binding protein administration failed to improve insulin resistance in diabetic or insulin-resistant patients [73]. Likewise, anti-TNF-α therapies in non-diabetic psoriatic patients did not significantly vary serum concentrations of both leptin and resistin [74]. Overall, the ability of TNF-α blockade in dampening both resistin and leptin levels is still debated and controversial, albeit the antiinflammatory effect of anti-TNF agents is more likely associated with an increased body weight, positively correlating with leptin serum levels, and a presumable reduction of insulin resistance.…”

Section: Tnf-αmentioning

confidence: 83%

Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity

Chiricozzi

Raimondo

Lembo

et al. 2016

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Psoriasis is a chronic skin disorder associated with several comorbid conditions. In psoriasis pathogenesis, the role of some cytokines, including TNF-α and IL-17, has been elucidated. Beside their pro-inflammatory activity, they may also affect glucose and lipid metabolism, possibly promoting insulin resistance and obesity. On the other hand, adipose tissue, secreting adipokines such as chemerin, visfatin, leptin, and adiponectin, not only regulates glucose and lipid metabolism, and endothelial cell function regulation, but it may contribute to inflammation. Areas covered: This review provides an updated 'state-of-the-art' about the reciprocal contribution of a small subset of conventional cytokines and adipokines involved in chronic inflammatory pathways, upregulated in both psoriasis and increased adiposity. A systematic search was conducted using the PubMed Medline database for primary articles. Expert commentary: Because psoriasis is associated with increased adiposity, it would be important to define the contribution of chronic skin inflammation to the onset of obesity and vice versa. Clarifying the pathogenic mechanism underlying this association, a therapeutic strategy having favorable effects on both psoriasis and increased adiposity could be identified.

show abstract

“…19 In contrast a lack of change in leptin levels was observed in 35 psoriasis patients after methotrexate treatment. 54 Treatment with acitretin for 3 months did not result in a significant change in leptin levels in one study of 34 patients with psoriasis. 35 Similarly, a decrease in leptin levels after 24 weeks of treatment with anti-TNF agents has been observed.…”

Section: Obesity Weight Loss and Psoriasismentioning

confidence: 99%

Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction

et al. 2017

View full text Add to dashboard Cite

Adipokines are secreted by white adipose tissue, an active endocrine organ, and play a role in the regulation of metabolic functions such as lipid metabolism, inflammation, and vascular homeostasis. Adipokines are secreted in excess in obesity and contribute to the development of associated comorbidities such as metabolic syndrome and atherosclerosis. Psoriasis, a chronic immune-mediated skin disease, is associated with obesity and increased cardiovascular risk. Understanding the role of adipokines in psoriasis may in part explain the association between psoriasis and cardiovascular disease. This review summarizes the data regarding key adipokines in patients with psoriasis and the change in adipokine profiles with psoriasis therapy. Adipokines may be mediators of cutaneous inflammation suggesting a role in the pathophysiology of psoriasis and the development of comorbidities.

show abstract

Relationship of Leptin with adiposity and inflammation and Resistin with disease severity in Psoriatic patients undergoing anti‐TNF‐alpha therapy

Abstract: In patients with moderate-to-severe psoriasis leptin correlates with metabolic syndrome features and inflammation whereas resistin correlate with inflammation and disease severity.

Cited by 31 publications

References 26 publications

Effects of secukinumab on serum adipocytokines: preliminary data

Effects of secukinumab on serum adipocytokines: preliminary data

Crosstalk between skin inflammation and adipose tissue-derived products: pathogenic evidence linking psoriasis to increased adiposity

Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction

Contact Info

Product

Resources

About